BioCryst Q3: Orladeyo's Power, Debt Cleared
Hello! Today, I've brought you an insightful dive into the recent Q3 2025 earnings call from BioCryst Pharmaceuticals (NASDAQ: BCRX). This call highlighted strong performance for their flagship drug, Orladeyo, strategic financial maneuvers, and exciting progress in their pipeline. It's a fantastic example of a company navigating a competitive landscape while fortifying its future. Let's break down the key takeaways! ☆ Orladeyo's Continued Dominance and Growth BioCryst's oral therapy, Orladeyo, continues to be a powerhouse, demonstrating impressive growth and resilience. The company reported a robust $159.1 million in total Orladeyo revenue for Q3 2025 , marking a significant 37% year-over-year increase . A substantial $141.6 million of this came from the US market , underscoring its strong domestic traction. Despite the introduction of new competitive therapies, Orladeyo has maintained its momentum. Management noted that new prescriptions continued at t...